hERG1 Potassium Channels: Novel Biomarkers in Human Solid Cancers

Because of their high incidence and mortality solid cancers are a major health problem worldwide. Although several new biomarkers and potential targets for therapy have been identified through biomolecular research in the last years, the effects on patients’ outcome are still unsatisfactory. Increas...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2015-01, Vol.2015 (2015), p.1-9
Main Authors: Bernini, Marco, Bencini, Lapo, Lottini, Tiziano, Lastraioli, Elena, Arcangeli, Annarosa
Format: Article
Language:English
Subjects:
Animals
Biomarkers, Tumor - biosynthesis
Biomarkers, Tumor - genetics
Biomedical research
Cancer
Cell Proliferation - genetics
Early Detection of Cancer
ERG1 Potassium Channel
Ether-A-Go-Go Potassium Channels - biosynthesis
Ether-A-Go-Go Potassium Channels - genetics
Gene Expression Regulation, Neoplastic
Health aspects
Humans
Mice
Neoplasms - genetics
Neoplasms - pathology
Physiological aspects
Potassium channels
Review
Translational Medical Research
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Because of their high incidence and mortality solid cancers are a major health problem worldwide. Although several new biomarkers and potential targets for therapy have been identified through biomolecular research in the last years, the effects on patients’ outcome are still unsatisfactory. Increasing evidence indicates that hERG1 potassium channels are overexpressed in human primary cancers of different origin and several associations between hERG1 expression and clinicopathological features and/or outcome are emerging. Aberrant hERG1 expression may be exploited either for early diagnosis (especially in those cancers where it is expressed in the initial steps of tumor progression) or for therapy purposes. Indeed, hERG1 blockage impairs tumor cell growth both in vitro and in vivo in preclinical mouse model. hERG1-based tumor therapy in humans, however, encounters the major hindrance of the potential cardiotoxicity that many hERG1 blockers exert. In this review we focus on recent advances in translational research in some of the most frequent human solid cancers (breast, endometrium, ovary, pancreas, esophagus, stomach, and colorectum) that have been shown to express hERG1 and that are a major health problem.
ISSN:2314-6133
2314-6141
DOI:10.1155/2015/896432